(19)
(11) EP 3 201 203 A1

(12)

(43) Date of publication:
09.08.2017 Bulletin 2017/32

(21) Application number: 15778162.6

(22) Date of filing: 29.09.2015
(51) International Patent Classification (IPC): 
C07D 498/08(2006.01)
A61P 1/00(2006.01)
A61P 25/06(2006.01)
A61P 25/18(2006.01)
A61P 25/24(2006.01)
 A61K 31/5386(2006.01)
A61P 1/08(2006.01)
A61P 25/16(2006.01)
A61P 25/22(2006.01)
A61P 25/30(2006.01)
(86) International application number:
PCT/US2015/052806
(87) International publication number:
WO 2016/053947 (07.04.2016 Gazette 2016/14)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA

(30) Priority: 29.09.2014 US 201462056982 P

(71) Applicant: Takeda Pharmaceutical Company Limited
Osaka-shi, Osaka 541-0045 (JP)

(72) Inventor:
  • ZHAO, Yuxin
    San Diego, California 92121 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)

   


(54) CRYSTALLINE FORM OF 1-(1-METHYL-1H-PYRAZOL-4-YL)-N-((1R,5S,7S)-9-METHYL-3-OXA-9-AZABICYCLO[3.3.1]NONAN-7-YL)-1H-INDOLE-3-CARBOXAMIDE